TriNetX analysis probes GLP-1 agonists and hematologic malignancy risk
Researchers propensity score-matched type 2 diabetes patients starting semaglutide, dulaglutide, liraglutide or exenatide against DPP-4 and SGLT2 inhibitor users.
PR
By Priya Raman · Science Reporter
Oct 12 10:47 ETSource: Nature
The wire
- 01Retrospective cohort study drew on the TriNetX federated network of over 100 million de-identified records, covering adults with type 2 diabetes who initiated a GLP-1 receptor agonist between January 1, 2015 and March 31, 2021.
- 02Long-term malignancy safety is a standing question for prescribers as GLP-1 indications widen to cardiovascular, renal and liver disease; active comparators were second-line agents used in the same period.
- 03The available text describes design only; effect estimates are not stated here, and retrospective claims-style analyses cannot establish causation. Preclinical rationale cited includes NF-kB suppression and immune modulation.
From the source
Read at nature.comGlucagon-like peptide-1 receptor agonists and risk for hematologic malignancies: a multicenter propensity score-matched analysis
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have become central to the management of type 2 diabetes mellitus (T2DM) and obesity, with indications now extending to cardiovascular risk reduction, renal protection, and liver disease [ 1 ]. As utilization of these agents continues to grow, thorough characterization of their long-term safety profile, including potential effects on malignancy
